Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 18/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193990 | 0.88 | EPHX2 (0.58) | EPHX2 | |
| SCHEMBL5560549 | 0.87 | EPHX2 (0.57) | EPHX2 | |
| SCHEMBL5554998 | 0.86 | EPHX2 (0.57) | EPHX2 | |
| SCHEMBL5587653 | 0.86 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL5588396 | 0.84 | EPHX2 (0.54) | EPHX2MEN1KMT2A | |
| SCHEMBL5559990 | 0.84 | EPHX2 (0.55) | EPHX2 | |
| SCHEMBL5555337 | 0.83 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL3794554 | 0.83 | EPHX2 (0.73) | EPHX2 | |
| SCHEMBL5560062 | 0.82 | EPHX2 (0.53) | EPHX2 | |
| SCHEMBL5560678 | 0.80 | EPHX2 (0.63) | HDAC4HDAC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455652-B2 | Inhibitors for the soluble epoxide hydrolase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-31 | — | — | US | disclosed |
| EP-1608319-A4 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1608319-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | The Regents of the University of California (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004089296-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | HDAC4 2429/4885HDAC1 2918/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.